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Abstract Introduction:
The blood pressure (BP) of most patients on antihypertensive monotherapy or bitherapy remains uncontrolled.
Our study evaluated the efficacy of triple therapy with perindopril, amlodipine, and indapamide sustained
release (SR) in patients with uncontrolled hypertension on previous antihypertensive therapy.
Methods:
This 4-month, multicenter, prospective, observational, open-label study included patients switched from
previous antihypertensive therapy to triple therapy with perindopril, amlodipine, and indapamide SR. The
main outcome was change in office BP from baseline to 4 months, as well as changes in 24-h ambulatory BP
monitoring (ABPM) parameters in a subgroup of patients.
Results:
Age was 62.8 ± 11.3 years in 6,088 patients (55 % were male). Office BP at baseline was
158.1 ± 13.0/92.6 ± 8.8 mmHg. By 4 months, office BP decreased by 26.7 ± 13.3/12.9 ± 9.4 mmHg (p < 0.001).
ABPM was performed in 62 patients. In these patients, 24-h systolic BP decreased (from 138.7 ± 12.5 to
125.5 ± 12.8 mmHg), as did 24-h diastolic BP (from 77.5 ± 11.4 to 70.4 ± 8.7 mmHg) (both p < 0.0001).
Heart rate remained unchanged. In patients previously on renin-angiotensin-aldosterone system (RAAS)
inhibitor/amlodipine, 24-h ambulatory systolic and diastolic BP decreased from 136.9 ± 12.8 to
125.4 ± 13.3 mmHg (p = 0.0003) and from 76.3 ± 12.6 to 70.2 ± 9.5 mmHg (p = 0.0005). In those previously
on RAAS inhibitor/hydrochlorothiazide, 24-h ambulatory systolic and diastolic BP decreased from
137.8 ± 12.7 to 122.7 ± 15.4 mmHg (p = 0.0039) and from 73.6 ± 9.4 to 65.7 ± 7.3 mmHg (p = 0.002). Most
(74 and 80 %, respectively) patients reached target ABPM values (<130/80 mmHg).
Conclusion:
A triple combination of perindopril, amlodipine, and indapamide SR controlled BP effectively in hypertensive
patients uncontrolled by previous antihypertensive monotherapy or bitherapy, including RAAS inhibitor/
amlodipine or RAAS inhibitor/hydrochlorothiazide combinations.
Footnote Information on behalf of the PAINT Investigators.
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
ORIGINAL RESEARCH ARTICLE1
2 Triple Combination Therapy in Hypertension:
3 The Antihypertensive Efficacy of Treatment with Perindopril,
4 Amlodipine, and Indapamide SR
5 De´nes Pa´ll • Ildiko´ Sza´nto´ • Zolta´n Szabo´
6
7  Springer International Publishing Switzerland 2014
8 Abstract
9 Introduction The blood pressure (BP) of most patients on
10 antihypertensive monotherapy or bitherapy remains
11 uncontrolled. Our study evaluated the efﬁcacy of triple
12 therapy with perindopril, amlodipine, and indapamide
13 sustained release (SR) in patients with uncontrolled
14 hypertension on previous antihypertensive therapy.
15 Methods This 4-month, multicenter, prospective, obser-
16 vational, open-label study included patients switched from
17 previous antihypertensive therapy to triple therapy with
18 perindopril, amlodipine, and indapamide SR. The main
19 outcome was change in ofﬁce BP from baseline to
20 4 months, as well as changes in 24-h ambulatory BP
21 monitoring (ABPM) parameters in a subgroup of patients.
22 Results Age was 62.8 ± 11.3 years in 6,088 patients
23 (55 % were male). Ofﬁce BP at baseline was
24 158.1 ± 13.0/92.6 ± 8.8 mmHg. By 4 months, ofﬁce BP
25 decreased by 26.7 ± 13.3/12.9 ± 9.4 mmHg (p\ 0.001).
26 ABPM was performed in 62 patients. In these patients,
27 24-h systolic BP decreased (from 138.7 ± 12.5 to
28 125.5 ± 12.8 mmHg), as did 24-h diastolic BP (from
29 77.5 ± 11.4 to 70.4 ± 8.7 mmHg) (both p\ 0.0001).
30 Heart rate remained unchanged. In patients previously on
31 renin-angiotensin-aldosterone system (RAAS) inhibitor/
32 amlodipine, 24-h ambulatory systolic and diastolic BP
33 decreased from 136.9 ± 12.8 to 125.4 ± 13.3 mmHg
34 (p = 0.0003) and from 76.3 ± 12.6 to 70.2 ± 9.5 mmHg
35 (p = 0.0005). In those previously on RAAS inhibitor/
36hydrochlorothiazide, 24-h ambulatory systolic and diastolic
37BP decreased from 137.8 ± 12.7 to 122.7 ± 15.4 mmHg
38(p = 0.0039) and from 73.6 ± 9.4 to 65.7 ± 7.3 mmHg
39(p = 0.002). Most (74 and 80 %, respectively) patients
40reached target ABPM values (\130/80 mmHg).
41Conclusion A triple combination of perindopril, amlo-
42dipine, and indapamide SR controlled BP effectively in
43hypertensive patients uncontrolled by previous antihyper-
44tensive monotherapy or bitherapy, including RAAS inhib-
45itor/amlodipine or RAAS inhibitor/hydrochlorothiazide
46combinations.
47
481 Introduction
49Hypertension is a severe public health problem with a
50prevalence of 35–40 % in the adult population [1]. Given the
51growing prevalence of excess weight and obesity, and aging
52of the hypertensive populations, a further increase in rate of
53hypertension is to be expected [2–4]. Hypertension enhances
54cardiovascular (CV) risk, which means that effectively
55reducing elevated blood pressure (BP) and reaching target
56BP values is expected to result in risk reduction. According
57to a recent meta-analysis, a decrease in systolic blood pres-
58sure (SBP) of 2 mmHg reduces the risks of stroke and cor-
59onary events by 10 and 7 %, respectively [5].
60Several factors contribute to the development of essen-
61tial hypertension, in particular increased circulating vol-
62ume, sympathetic hyperactivity, increased total peripheral
63vascular resistance, and abnormal overactivity of the renin-
64angiotensin-aldosterone system (RAAS). In the majority of
65hypertensive patients, the cumulative effects of numerous
66factors contribute to high BP, making it hard to control: up
67to 70 % of hypertensive patients need combination therapy
68[6, 7], and earlier use of single-pill combinations in the
A1 on behalf of the PAINT Investigators.
A2 D. Pa´ll (&)  I. Sza´nto´  Z. Szabo´
A3 Department of Medicine, Clinical Center, University of
A4 Debrecen, Nagyerdei krt 98 Pf 19, 4032 Debrecen, Hungary
A5 e-mail: pall.denes@gmail.com
Journal : Large 40261 Dispatch : 9-8-2014 Pages : 8
Article No. : 223
h LE h TYPESET
MS Code : CDIA-D-14-00032 h CP h DISK4 4
Clin Drug Investig
DOI 10.1007/s40261-014-0223-0
A
u
th
o
r
 P
r
o
o
f
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
69 treatment of hypertension appears beneﬁcial in terms of BP
70 control and CV event reduction [8, 9]. Combining two
71 antihypertensive agents from different classes has also
72 been shown to be a more effective way of reducing BP than
73 doubling the dose of a single agent [10]. Despite the
74 advantages of dual- vs. monotherapy, dual-agent antihy-
75 pertensive combinations still fail to control BP in over half
76 (60 %) of hypertensive patients [7].
77 The 2007 Guidelines of the European Society of
78 Hypertension (ESH)/European Society of Cardiology
79 (ESC) recommend ﬁve classes of antihypertensive as ﬁrst-
80 line treatment: diuretics, beta-blockers, calcium channel
81 blockers (CCBs), angiotensin-converting enzyme (ACE)
82 inhibitors, and angiotensin receptor blockers (ARBs) [2].
83 As most hypertensive patients require combination therapy,
84 this ﬁrst-line approach needs reconsideration. The 2009
85 update of the ESH/ESC guidelines suggested slight modi-
86 ﬁcations and shifts in emphasis, based on new studies [11].
87 The latest 2013 ESH/ESC guidelines have underlined the
88 faster response to combination therapy in most patients, a
89 better chance of achieving target BP in patients with higher
90 BP, and improved patient adherence [12].
91 1.1 Aim
92 PAINT (Perindopril-Amlodipine plus Indapamide combi-
93 nation for controlled hypertension Non-intervention Trial)
94 was principally designed to investigate the antihyperten-
95 sive efﬁcacy of a triple combination of antihypertensive
96 drugs—perindopril, amlodipine, and indapamide sustained
97 release (SR)—in patients who had not reached target BP
98 values with previous antihypertensive treatment. As a
99 secondary aim, changes in metabolic parameters were
100 analyzed.
101 2 Patients and methods
102 Male or female Hungarian outpatients aged[18 years with
103 primary hypertension took part in this prospective, multi-
104 center, observational study. Grade 1 (mild) hypertension
105 was classiﬁed as SBP 140–159 mmHg or diastolic blood
106 pressure (DBP) 90–99 mmHg; grade 2 (moderate) hyper-
107 tension as SBP 160–179 mmHg or DBP 100–109 mmHg;
108 and grade 3 (severe) hypertension as SBP C180 mmHg or
109 DBP C110 mmHg. Patients had uncontrolled BP on pre-
110 vious antihypertensive treatment [target of ofﬁce \140/
111 90 mm Hg; or \130/80 mmHg if ambulatory blood
112 pressure monitoring (ABPM) data were available or if the
113 patient had diabetes mellitus, metabolic syndrome, coro-
114 nary heart disease, peripheral vascular disease, cerebro-
115 vascular disease, or chronic renal insufﬁciency] and were
116 enrolled if their physician had planned to switch their
117antihypertensive therapy to ﬁxed-dose combination perin-
118dopril/amlodipine 5/5, 5/10, 10/5, or 10/10 mg (Coveram
,
119Servier, Suresnes, France) plus indapamide SR 1.5 mg
120(Natrilix SR
, Servier). Patients with contraindications to
121any of these agents were excluded. Concomitant use of
122other RAAS inhibitors, CCBs, and/or diuretics was not
123permitted, but the concurrent use of other antihypertensive
124therapy, e.g., beta-blockers, alpha-adrenoreceptor blockers,
125and/or centrally acting antihypertensive drugs, was
126allowed. The decision on what dosage should be prescribed
127was made by physicians on the basis of recent BP values
128and existing comorbidities.
129Because of the study’s observational nature, ofﬁce BP
130was measured in accordance with the usual method
131employed by the participating physician at baseline and
1324 months. Patients from the main study who underwent
133ABPM as part of their follow-up were included as a sub-
134group in which ABPM and laboratory tests were performed
135at baseline and after 4 months using Meditech ABPM-04
136or ABPM-05 devices (Meditech Ltd., Budapest, Hungary),
137validated by both the British Hypertension Society and the
138Association for the Advancement of Medical Instrumen-
139tation [13, 14]. Monitors were placed in the morning, and
140measurements were taken every 15 min during the day and
141every 30 min at night. From these measurements, 24-h
142daytime and night-time SBP and DBP, and heart rate were
143calculated. Percent time elevation was the percentage of
144the whole monitoring period when BP exceeded normal
145values ([140/90 mmHg during daytime and [120/
14680 mmHg during nighttime). Trough-to-peak (T/P) ratio
147was measured to characterize the quality of BP reduction.
148Laboratory parameters were determined at the discretion of
149the physician at baseline and after 4 months and included
150total cholesterol, low-density lipoprotein cholesterol, high-
151density lipoprotein cholesterol, triglycerides, fasting glu-
152cose, serum creatinine, uric acid, potassium, and sodium.
153Adverse events were recorded on speciﬁc case report forms
154over the 4 months of the study.
155All patients provided written informed consent. This
156study was performed in accordance with the ethical stan-
157dards described in the Declaration of Helsinki and was
158approved by the appropriate ethics committee (ETT-TU-
159KEB-NIT approval number: 4975-0/2010-1018EKU
160333/PI/10).
1612.1 Statistical methods
162Baseline characteristics are summarized as means ± stan-
163dard deviations for continuous variables, and numbers of
164patients and percentages for categorical variables, and
165analyses were performed on an intention-to-treat basis.
166Mean changes in ofﬁce BP are shown according to severity
167of hypertension and previous monotherapy or RAAS
D. Pa´ll et al.
Journal : Large 40261 Dispatch : 9-8-2014 Pages : 8
Article No. : 223
h LE h TYPESET
MS Code : CDIA-D-14-00032 h CP h DISK4 4
A
u
th
o
r
 P
r
o
o
f
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
168 inhibitor bitherapy, as well as according to perindopril/
169 amlodipine dosage during the study (5/5, 5/10, 10/5, or
170 10/10 mg). In the ABPM subgroup, changes in mean SBP
171 and DBP are shown according to severity of hypertension
172 at baseline, as well as before and after treatment. A paired
173 t test was used to assess whether changes in ofﬁce- or
174 ABPM-assessed SBP and DBP from baseline to 4 months
175 were signiﬁcant. Signiﬁcance was deﬁned as p value
176 \0.05. Data were collected and analyzed in accordance
177 with the European Guidelines for Good Clinical Practice/
178 ICH guidelines. Planimeter Kft. (Budapest, Hungary), an
179 independent statistics company, analyzed all study data
180 using SAS software (version 9.3).
181 3 Results
182 3.1 Baseline Characteristics
183 Mean age of the 6,088 patients in our study was
184 62.8 ± 11.3 years, and they had had hypertension for
185 11.2 ± 8.2 years. Most patients (90 %) had mild
186 (n = 2,424) or moderate (n = 3,033) hypertension on
187 previous antihypertensive treatment; some (n = 631) had
188 severe hypertension. Over a third of patients had previously
189 received three or more antihypertensive agents [n = 2,164
190 (36 %)] and over a third had received two antihypertensive
191 agents [n = 2,240 (37 %)]; 28 % (n = 1,684) had received
192 one antihypertensive agent. Other demographic and base-
193 line data are presented in Table 1.
194 3.2 Ofﬁce Blood Pressure
195 Mean ofﬁce SBP decreased signiﬁcantly from
196 158.1 ± 13.0 to 131.4 ± 8.4 mmHg from baseline to
197 4 months with perindopril/amlodipine/indapamide SR, and
198 mean DBP decreased signiﬁcantly from 92.6 ± 8.8 to
199 79.7 ± 6.2 mmHg (BP change, 26.7 ± 13.3/12.9 ±
200 9.4 mmHg; p\ 0.001). The reductions in both ofﬁce SBP
201 and DBP were baseline dependent (Fig. 1); in cases where
202 hypertension was more severe, the decrease in BP was
203 greater. BP decreased signiﬁcantly in all patients who
204 previously took RAAS inhibitors or amlodipine mono-
205 therapy or ACE inhibitor- or ARB-based single-pill com-
206 binations (all p\ 0.0001) (Fig. 2). The percentages of
207 patients who achieved ofﬁce BP control at the end of the
208 study were 75, 76, and 78 % in patients previously
209 receiving three or more, two, or one antihypertensive
210 agent(s), respectively.
211 BP was also found to decrease signiﬁcantly in each of
212 the four dosage-based subgroups of perindopril/amlodi-
213 pine/indapamide SR (all p\ 0.0001) (Fig. 3). Ofﬁce BP
214 target was achieved after 4 months’ treatment with
Table 1 Baseline characteristics in the 6,088 patients. Values are
mean ± standard deviation or numbers and percentages
Parameter Whole population (n = 6,088)
Demographic parameters
Age (years) 62.8 ± 11.3
Male 3,353 (55 %)
Waist circumference (cm) 99.4 ± 13.3
Blood pressure parameters
Systolic blood pressure (mmHg) 158.1 ± 13.0
Diastolic blood pressure (mmHg) 92.6 ± 8.8
Duration of hypertension (years) 11.2 ± 8.2
Risk factors
Dyslipidemia 3,209 (53 %)
Obesity 3,157 (52 %)
Smoking 1,836 (30 %)
Prediabetes 773 (13 %)
Comorbidities
Diabetes mellitus 1,605 (26 %)
Ischemic heart disease 1764 (29 %)
Transient ischemic attack/stroke 721 (12 %)
Renal disease 253 (4 %)
Peripheral vascular disease 613 (10 %)
Chronic heart failure 412 (7 %)
Fig. 1 Changes in ofﬁce blood pressure from baseline to 4 months,
according to severity of hypertension. Values are means ± standard
deviations. *p\ 0.001 vs. baseline. Mild hypertension (grade 1),
systolic blood pressure (SBP) 140–159 mmHg, and/or diastolic blood
pressure (DBP) 90–99 mmHg; moderate hypertension (grade 2), SBP
160–179 mmHg and/or DBP 100–109 mmHg; and severe hyperten-
sion (grade 3), SBP C180 mmHg and/or DBP C110 mmHg
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215 perindopril/amlodipine/indapamide SR by C70 %, regard-
216 less of dosage. The target was achieved by 80, 77, 73, and
217 71 % of patients on perindopril/amlodipine 5/5, 5/10, 10/5,
218 and 10/10 mg plus indapamide SR 1.5 mg, respectively.
219 Over the course of the study, the percentage of patients on
220 perindopril/amlodipine 5/5 mg plus indapamide SR 1.5 mg
221 decreased from 46 to 36 % (2,805–2,203 patients), while
222 the percentage on perindopril/amlodipine 10/10 mg plus
223 indapamide SR 1.5 mg increased from 25 to 33 %
224 (1,500–1,994 patients). Smaller changes were observed in
225 the use of perindopril/amlodipine 5/10 mg plus indapamide
226 SR 1.5 mg (7 vs. 7 %; 399 vs. 397 patients) and perin-
227 dopril/amlodipine 10/5 mg plus indapamide SR 1.5 mg (23
228 vs. 25 %; 1,384 vs. 1,494 patients).
229 3.3 ABPM Results
230 In total, 62 patients underwent ABPM. Thirty-four patients
231 were previously on three ormore antihypertensive agents, 14
232 were on antihypertensive bitherapy, and 14 were on anti-
233 hypertensive monotherapy. At baseline, mean 24-h BP was
234 138.7 ± 12.5/77.5 ± 11.4 mmHg. Switching to perindo-
235 pril/amlodipine/indapamide SR for 4 months signiﬁcantly
236 reduced both mean 24-h SBP and DBP to 125.5 ±
23712.8/70.4 ± 8.7 mm Hg (-13.2 ± 13.7 and -7.1 ± 9.0
238mmHg, respectively; both p\ 0.0001), and normalized
239ofﬁce BP in[80 % (n = 50) of patients. The reductions in
240mean 24-h BP were 10.2 ± 13.8/6.0 ± 8.7 mmHg in grade
2411 patients (n = 20), 13.2 ± 13.9/7.8 ± 9.3 mmHg in grade
2422 patients (n = 33), and 19.6 ± 12.0/7.2 ± 9.7 mmHg in
243grade 3 patients (n = 9) (all p\ 0.0001) (Fig. 4). Overall,
244heart rate remained unchanged with this therapy (71.6 ± 8.9
245vs. 70.0 ± 8.8 bpm; p = not signiﬁcant).
246Analyzing daytime BP revealed signiﬁcant reductions
247in both systolic and diastolic values [142.6 ± 13.7 at
248baseline vs. 129.2 ± 13.7 mmHg at 4 months for SBP;
249and 80.9 ± 13.0 at baseline vs. 73.6 ± 9.7 mmHg at
2504 months for DBP (both p\ 0.0001)]. Similar reductions
251in night-time BP were observed: SBP fell from a baseline
252value of 130.8 ± 14.3 to 118.0 ± 13.6 mmHg, while
253DBP fell from 70.8 ± 9.7 to 64.2 ± 8.4 mmHg
254(p\ 0.0001).
255Reduction in percent time elevation was signiﬁcant for
256both SBP (72.5 ± 24.8 vs. 45.2 ± 31.6 %; p\ 0.0001)
257and DBP (43.0 ± 34.2 vs. 21.8 ± 23.9 %; p\ 0.0001).
258The diurnal index, which represents differences in daytime
259and night-time BP, increased slightly during the study
260before normalizing at the end of the observation period
Fig. 2 Changes in ofﬁce blood pressure from baseline to 4 months in
patients previously on angiotensin-converting enzyme (ACE) inhib-
itor, angiotensin receptor blocker (ARB), or amlodipine monotherapy
(left-hand panels) or on ACE inhibitor- or ARB-based single-pill
combinations (right-hand panels). Values are means ± standard
deviations. HCTZ, hydrochlorothiazide. *p\ 0.0001 vs. baseline
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261 [systolic value: 7.9 ± 9.1 vs. 8.5 ± 7.5 %; diastolic value:
262 11.7 ± 9.2 vs. 12.3 ± 8.5 % (both p = not signiﬁcant)].
263 In patients on single-pill RAAS inhibitor/amlodipine
264 (n = 18) switched to triple therapy, 24-h SBP decreased
265 from 136.9 ± 12.8 at baseline to 125.4 ± 13.3 mmHg at
266 4 months (p = 0.0003), and 24-h DBP from 76.3 ± 12.6
267 to 70.2 ± 9.5 mmHg (p = 0.0005). There was no change
268 in heart rate (70.6 ± 8.1 to 69.2 ± 9.7 bpm; p = 0.54). In
269 patients on single-pill RAAS inhibitor/hydrochlorothiazide
270 (HCTZ) switched to triple therapy (n = 10), 24-h SBP
271 decreased from 137.8 ± 12.7 at baseline to
272 122.7 ± 15.4 mmHg at 4 months (p = 0.0039), and 24-h
273 DBP from 73.6 ± 9.4 to 65.7 ± 7.3 mmHg (p = 0.002).
274 Again, there was no change in heart rate (70.8 ± 10.7 to
275 71.9 ± 11.3 bpm; p = 0.43). Target 24-h ABPM values
276 (\130/80 mmHg) were attained in 74 and 80 % of patients
277 switched from single-pill RAAS inhibitor/amlodipine or
278 RAAS inhibitor/HCTZ, respectively.
279 Reductions inBPwere signiﬁcant at each hour and in each
280 hypertensive-class subgroup (10.1–15.4/5.1–7.8 mmHg;
281 p\ 0.001; Fig. 5). The T/P ratio with perindopril/amlodi-
282 pine/indapamide SR was 75 % for SBP and 70 % for DBP.
2833.4 Changes in Metabolic Parameters
284Positive changes in metabolic parameters were also
285observed in the total study population. Total cholesterol
286decreased from 5.8 ± 1.1 to 5.2 ± 0.9 mmol/L, low-den-
287sity–lipoprotein cholesterol from 3.3 ± 1.1 to 2.9 ±
2880.9 mmol/L, triglycerides from 2.1 ± 1.1 to 1.9 ± 1.5
289mmol/L, and blood glucose levels from 6.3 ± 1.7 to
2905.9 ± 1.4 mmol/L (all p\ 0.0001). High-density–lipo-
291protein cholesterol increased from 1.3 ± 0.4 mmol/L to
2921.4 ± 0.4 mmol/L (p = 0.0003).
2933.5 Safety
294In the overall population (n = 6088), there were no serious
295adverse events. Patients experienced 43 adverse events
296during the study that were deemed drug related (0.7 %).
297The most common of these was ankle edema (n = 34;
2980.6 %), but dizziness (n = 3;\0.1 %), headache (n = 3;
299\0.1 %), cough (n = 2; \0.1 %), and ﬂushing (n = 1;
300\0.1 %) were also observed.
Fig. 3 Changes in ofﬁce systolic and diastolic blood pressure from
baseline to 4 months, according to dosage of perindopril/amlodipine
during the study. Values are means ± standard deviations in patients
receiving indapamide sustained release 1.5 mg. *p\ 0.0001 vs.
baseline
Fig. 4 The effect of perindopril/amlodipine/indapamide sustained
release on systolic and diastolic blood pressure according to severity
of hypertension, as measured by ambulatory blood pressure monitor-
ing from baseline to 4 months (n = 62). Values are means ± stan-
dard deviations. *p\ 0.0001 vs. baseline
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301 4 Discussion
302 Switching hypertensive patients with uncontrolled BP on
303 previous antihypertensive treatment to one of four dosages
304 of a triple combination of perindopril/amlodipine/indapa-
305 mide SR resulted in signiﬁcant reductions in ofﬁce and
306 24-h BP after 4 months, regardless of the dosage of triple
307 therapy used or severity of hypertension at baseline. Ofﬁce
308 BP targets were achieved by most patients after 4 months’
309 treatment. Metabolic parameters improved over the course
310 of the study, adverse effects observed were those expected,
311 and the incidence of adverse effects in the overall popu-
312 lation was low. Our study conﬁrms a previous ﬁnding that
313 triple antihypertensive combination therapy with a RAAS
314 inhibitor, CCB, and diuretic reduces BP more than com-
315 ponent dual-combination treatment [10]. It also conﬁrms
316 recent ﬁndings showing that antihypertensive triple therapy
317 in general [15, 16], and this triple combination in particular
318 [17], reduce BP in hypertension.
319 Recent recommendations have emphasized the impor-
320 tance of inhibiting excess RAAS activity in the treatment
321 of primary hypertension [2, 11]. Inhibition of an overactive
322 RAAS can be achieved either with ACE inhibitors or
323 ARBs, although recent meta-analyses have shown that
324 ACE inhibitors may be better at reducing risk of CV and
325 all-cause mortality [18, 19]. CCBs and diuretics can be
326 added to ACE inhibitors to obtain an additional antihy-
327 pertensive effect. The CCB with the most evidence for
328 beneﬁcial effects is the third-generation dihydropyridine
329 amlodipine. With respect to diuretics, current evidence
330 favors indapamide over HCTZ [20]. These combinations
331are recommended for priority use by current European
332hypertension guidelines [12]. Recent results from a post
333hoc analysis of ADVANCE (Action in Diabetes and Vas-
334cular disease: preterAx and diamicroN MR Controlled
335Evaluation) patients with type 2 diabetes mellitus showed
336that the addition of CCB to treatment with single-pill
337perindopril/indapamide signiﬁcantly reduced the relative
338risk of all-cause mortality by 28 % compared with patients
339receiving standard therapy that included a CCB [21].
340T/P ratio is an important indicator of duration of effect
341[22] and the SBP (75 %) and DBP (70 %) T/P ratios with
342triple therapy were above 66 %, the T/P threshold for safe
343single-daily-dose administration. This conﬁrms the ratio-
344nale for daily dosing with triple therapy. The circadian BP
345dipping proﬁle was normalized by treatment, as seen by
346changes in systolic and diastolic diurnal index ([10 %).
347Antihypertensive regimens that include single-pill combi-
348nations are simpler, and improvements in patient compli-
349ance have been shown to lead to better BP reduction and
350control [10].
351Throughout the 4-month observation period, signiﬁcant
352beneﬁcial changes were found in metabolic parameters:
353both blood glucose and lipid levels were reduced signif-
354icantly. This might be due to the switching of many
355patients on HCTZ to the metabolically neutral agent,
356indapamide SR, used in this study [23], and also to the
357close follow-up of participants, which might have
358encouraged better compliance. The improvement in met-
359abolic parameters seen with the combination of the three
360antihypertensive agents used in this study is in line with
361previous observations [17].
Fig. 5 Changes in mean
systolic and diastolic blood
pressure before (baseline, dark
gray lines) and after (4 months,
light gray lines) switch to triple
therapy with perindopril/
amlodipine/indapamide
sustained release in the
ambulatory blood pressure
monitoring subgroup (n = 62)
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362 Antihypertensive triple combinations also have the
363 potential to reduce the severity and incidence of adverse
364 effects. The severity of adverse effects may be minimized
365 by combining antihypertensive agents with complementary
366 modes of action [24]. ACE inhibitors in combination with
367 CCBs have been shown to reduce the incidence of CCB-
368 associated edema and diuretic-associated hypokalemia [24,
369 25]. The low incidence of adverse effects observed in this
370 study may be attributable to these speciﬁc ACE inhibitor-
371 and dihydropyridine CCB-related mechanisms of action,
372 plus the metabolic neutrality of indapamide SR [26].
373 4.1 Limitations
374 Single-arm, open-label studies such as ours do not use
375 randomized protocols. However, our ﬁndings do give an
376 indication of the value of perindopril/amlodipine/indapa-
377 mide SR in real-life clinical practice. Although only short-
378 term beneﬁt was evaluated here, the efﬁcacy and safety of
379 all three agents have been determined in international
380 randomized controlled trials of several years’ duration [27–
381 29]. It can also be difﬁcult to determine if a drug in a
382 combination is ineffective [12]. However, the advantages
383 of initiating antihypertensive therapy with a combination in
384 patients with markedly elevated BP or at high/very high
385 CV risk outweigh this constraint. The use of additional
386 antihypertensive agents, which could have impacted our
387 results, was not noted. The geographical scope of recruit-
388 ment was limited to one country, but these data give a good
389 picture of CV risk in hypertensive patients at a national
390 level, which is of interest [30].
391 5 Conclusion
392 The triple combination of amlodipine, perindopril, and
393 indapamide SR controlled BP effectively in hypertensive
394 patients not controlled on previous antihypertensive
395 monotherapy or bitherapy, including RAAS inhibitor/
396 amlodipine or RAAS inhibitor/HCTZ combinations.
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